Pluri
Pluri Biotech is a global leader in cell expansion technology, developing platforms to manufacture the products and solutions of the future across various industries including food, health, and agriculture. The company harnesses patented technology to develop and manufacture next-generation cell-based products, aiming to improve human well-being, increase sustainability, and address global challenges. With a strong track record of success, including over 250 patents and collaborations with major regulatory agencies and research institutions, Pluri is committed to innovation and scientific advancement. The company is dedicated to making its technologies accessible and sustainable, with a focus on advancing global health and environmental goals.
Industries
Nr. of Employees
medium (51-250)
Products
Placenta‑derived allogeneic cell therapy candidates
Allogeneic cell therapy candidates derived from expanded placenta‑origin cells intended for multiple clinical indications and formulated for off‑the‑shelf use.
Hematopoietic‑supporting cell therapy candidate (early‑phase)
An early‑phase allogeneic cell therapy program evaluated in Phase I clinical studies showing safety and signals of hematopoietic support, including reductions in transfusion requirements and increases in blood cell counts.
Cell therapy candidate for acute radiation syndrome (medical countermeasure)
Cell‑based candidate developed and evaluated in preclinical studies and regulatory filings as a medical countermeasure to support bone marrow recovery after high‑dose radiation exposure.
Cell‑based cultivated food product development
Development and commercialization of cultivated meat, seafood and plant‑cell raw materials using adapted cell expansion and bioprocess methods.
Placenta‑derived allogeneic cell therapy candidates
Allogeneic cell therapy candidates derived from expanded placenta‑origin cells intended for multiple clinical indications and formulated for off‑the‑shelf use.
Hematopoietic‑supporting cell therapy candidate (early‑phase)
An early‑phase allogeneic cell therapy program evaluated in Phase I clinical studies showing safety and signals of hematopoietic support, including reductions in transfusion requirements and increases in blood cell counts.
Cell therapy candidate for acute radiation syndrome (medical countermeasure)
Cell‑based candidate developed and evaluated in preclinical studies and regulatory filings as a medical countermeasure to support bone marrow recovery after high‑dose radiation exposure.
Cell‑based cultivated food product development
Development and commercialization of cultivated meat, seafood and plant‑cell raw materials using adapted cell expansion and bioprocess methods.
Services
CDMO services for cell‑based therapeutics
On‑site contract development and GMP manufacturing support for external cell therapy programs, including process development and clinical supply integration.
Platform licensing and technology transfer for cultivated food
Licensing and partnership services to transfer cell expansion and bioprocess methods for cultivated meat, seafood and plant‑cell production.
Cryopreservation and cold‑chain distribution support
Development and implementation of cryopreservation protocols, validated logistics methods and point‑of‑care handling procedures for global shipping of cryopreserved cell products.
Regulatory submission and engagement support
Advisory and preparation services for regulatory submissions and interactions with authorities, including IND/IDE preparation and strategies for special regulatory pathways.
CDMO services for cell‑based therapeutics
On‑site contract development and GMP manufacturing support for external cell therapy programs, including process development and clinical supply integration.
Platform licensing and technology transfer for cultivated food
Licensing and partnership services to transfer cell expansion and bioprocess methods for cultivated meat, seafood and plant‑cell production.
Cryopreservation and cold‑chain distribution support
Development and implementation of cryopreservation protocols, validated logistics methods and point‑of‑care handling procedures for global shipping of cryopreserved cell products.
Regulatory submission and engagement support
Advisory and preparation services for regulatory submissions and interactions with authorities, including IND/IDE preparation and strategies for special regulatory pathways.
Expertise Areas
- 3D cell culture and bioreactor platform development
- Allogeneic cell therapy development and off‑the‑shelf cell banking
- GMP biomanufacturing and automated aseptic production
- CMC preparation and multi‑jurisdictional regulatory submissions
Key Technologies
- 3D cell culture and bioreactors
- Automated aseptic manufacturing systems
- GMP production workflows
- Serum‑free cell culture media